BURNABY, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,098,362 common shares, which includes 1,229,508 shares sold upon the full exercise of the underwriters' option to purchase additional shares, and pre-funded . A Phase 1b proof-of-concept trial is underway evaluating the safety and tolerability of PCRX301 administered as a single-dose, popliteal fossa block in patients undergoing bunionectomy, with data now anticipated in the second quarter of this year. Key secondary endpoints include the proportion of patients experiencing 50% reduction in seizure frequency from baseline for XEN1101 versus placebo, MPC at Week 1 compared to baseline to assess the rapidity of seizure reduction and the Patient Global Impression of Change (PGI-C) at Week 12. X-TOLE2 is expected to be initiated in the second half of 2022 followed by the initiation of X-TOLE3 and both studies will run in parallel. BURNABY, British Columbia, March 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the year ended December 31, 2021 and provided a corporate update. On October 4, 2021, Xenon reported positive topline results from the Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in adult patients with focal epilepsy. In addition, we have now filed an IND with the FDA to support the initiation of our company-sponsored Phase 2 XEN1101 clinical trial in major depressive disorder, anticipated to commence in the first half of this year., Mr. Mortimer added, Patient enrollment is ongoing in our pediatric XEN496 Phase 3 EPIK clinical trial, which is expected to be completed in the first half of 2023. Road, INDORE - 452001 (M.P). Helping To Maintain Vision, Hearing Ability And Healthy . These multicenter, randomized, double-blind, placebo-controlled trials will evaluate the clinical efficacy and safety of XEN1101 administered as adjunctive treatment in patients with FOS. Eligibility criteria include adults aged 18 to 75 years old taking one to three anti-seizure medications (ASMs) with a seizure frequency of 4 seizures per month at baseline. Other income for the year ended December 31, 2021 was $0.1 million compared to $2.2 million for the same period in 2020. Xenon Pharmaceuticals Is An Ethical Pharma Company. We are here to serve the Masses. General and administrative expenses for the year ended December 31, 2021 were $22.0 million compared to $12.9 million for the same period in 2020. Xenon Pharmaceuticals Advancing a novel product pipeline of neurology therapies View Product Pipeline About We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. For more information about working at Xenon, please contact: careers@xenon-pharma.com General Inquiries Xenon Pharmaceuticals Inc. 3650 Gilmore Way Burnaby, BC V5G 4W8 Tel: 604.484.3300 Fax: 604.484.3450 info@xenon-pharma.com Medical Affairs Xenon is not currently recruiting patients for epidemiology or genetic research studies. Xenon continues to execute on its comprehensive strategy to protect and expand the intellectual property portfolio that covers XEN1101. info@xenon-pharma.com. BURNABY, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,098,362 common shares, which includes 1,229,508 shares sold upon the full exercise of the underwriters option to purchase additional shares, and pre-funded warrants to purchase 327,868 common shares. A Phase 2 proof-of-concept trial called X-NOVA is currently underway, along with an investigator led study with collaborators at the Icahn School of Medicine at Mount Sinai. Seizure frequency continued to improve for the OLE population during the first month after the 8-week double-blind period (DBP), suggesting that the efficacy signal has the potential to persist, and may potentially improve, in the planned 12-week DBP of the XEN1101 Phase 3 trials. : 01662-246253, 246252. We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Based on our prior market research, we believe XEN1101 could offer a compelling value proposition for focal epilepsy patients with residual seizure burden if approved. Skip to content. On June 21, 2022, Xenon announced completion of an End-of-Phase 2 (EOP2) meeting with the U.S. FDA. Greater Boston, primarily Boston and Cambridge, is home to almost 1,000 biotechnology companies, ranging from small start-ups to billion-dollar pharmaceutical companies. 6105, or by email atsyndicate@svbsecurities.com; orStifel, Nicolaus & Company, Incorporated,One Montgomery Street, Suite 3700,San Francisco, CA94104, Attn: Syndicate, or by phone at (415) 364-2720, or by email atsyndprospectus@stifel.com. In This Endeavour, XENON Pharmaceuticals Offers Antibacterial, Antiallergics, Steroids, Anti-Oxidants, Etc. Our novel product pipeline of neurology therapies addresses areas of high unmet medical need, with a focus on epilepsy. Xenon Pharma PVT. Our novel product pipeline of neurology therapies addresses areas of high unmet medical need, with a focus on epilepsy. Minimum 15 minutes delayed. Our XEN1101-related presentations have been posted here. (Common Stock) Data Provided by Refinitiv. Neurocrine Biosciences has an exclusive license to XEN901, now known as NBI-921352, a selective Nav1.6 sodium channel inhibitor. Neurocrine Biosciences is conducting a Phase 2 clinical trial evaluating NBI-921352 in adult patients with focal onset seizures, with data expected in 2023. Burnaby, BC V5G 4W8, Tel: 604.484.3300 XEN1101 continues to be generally well-tolerated in the OLE with adverse events (AEs) consistent with other anti-seizure medicines and the X-TOLE double-blind period. 1 min read. Their latest funding was raised on Jun 22, 2022 from a Post-IPO Equity round. BURNABY, British Columbia , Sept. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat presentation at the 17th Annual Wells Fargo . In addition, a Phase 2 clinical trial is underway evaluating NBI-921352 in patients aged between 2 and 21 years with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE). Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at theAnnual Meeting of the American Epilepsy Society (AES 2022), Xenon Pharmaceuticals to Present at the Bank of America Securities Biotech SMID Cap Conference 2022, Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences. 3650 Gilmore Way The increase of $9.0 million was primarily attributable to increased salaries and benefits from additional headcount, stock-based compensation expense, market research costs and legal fees for intellectual property protection. - Mr. C. M. Joshi (Prop.) Vikas Puri New Delhi 110018; Home; About Us; Our Products. PCRX301 (formerly FX301)In November 2021, Pacira BioSciences, Inc. completed its acquisition of Flexion Therapeutics, Inc., which included Flexions global rights to develop and commercialize XEN402, a Nav1.7 inhibitor also known as funapide. Our U.S. Company (Xenon Pharmaceuticals USA Inc.) is based in the Boston area. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. NASDAQ XENE (Common Stock) $38.89 1.96 Data Provided by Refinitiv. NBI-921352Xenon has an ongoing collaboration with Neurocrine Biosciences to develop treatments for epilepsy. It Offers High Quality Products With Attractive Packing, Reasonable Prices And Dedicated Service Focussed On Eye & ENT Care. Price: - On Genuine Enquiry. It Offers High Quality Products With Attractive Packing, Reasonable Prices And Dedicated Service Focussed On Eye & ENT Care. The trial met its primary efficacy endpoint with XEN1101 demonstrating a statistically significant and dose-dependent reduction from baseline in monthly (defined as 28 days) focal seizure frequency when compared to placebo (monotonic dose response; p<0.001). Copyright 2001 2022 Xenon All rights reserved. You can contact us for more details call us:+91 9310577789. Xenon has initiated its XEN1101 Phase 3 development program, which includes two identical Phase 3 clinical trials called X-TOLE2 and X-TOLE3, which are designed closely after the Phase 2b X-TOLE clinical trial. A focal seizure is localized within the brain and can either stay localized or spread to the entire brain, which is typically categorized as a secondary generalized seizure. Monopoly working rights in your selected towns. Xenon anticipates that the EPIK study will be completed in the first half of 2023. (MD of the Company) Based on the strength of data from this time course to efficacy analysis, a key secondary endpoint in the Phase 3 trials will include the median percent change of weekly FOS at Week 1. The topline data showed all primary and secondary seizure reduction endpoints were statistically significant across all dose groups, including the primary endpoint of median reduction from baseline in monthly seizure frequency and in the key secondary endpoint of patients with at least a 50% reduction in monthly focal seizure frequency from baseline, with p-values of <0.001 for both the 20 mg and 25 mg dose groups. Pursuant to the terms of the agreement, Xenon has the potential to receive certain clinical, regulatory, and commercial milestone payments, as well as future sales royalties. Xenon Pharmaceuticals Inc. (XENE) Stock Historical Prices & Data - Yahoo Finance Xenon Pharmaceuticals Inc. (XENE) NasdaqGM - NasdaqGM Real Time Price. We are developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, major depressive disorder (MDD), and potentially other neurological disorders. Land Line No. XEN496XEN496, a Kv7 potassium channel opener, is a proprietary pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE). The Series 1 Preferred Shares are convertible into common shares on a one-for-one basis at the option of the holder, subject to certain limitations. Focal seizures account for approximately 60% of seizures in the U.S., which results in a total focal onset seizure patient population of approximately 1.8 million patients. All other trademarks belong to their respective owner. XENE. The webcast will be broadcast live on the Investors section of the Xenon website. As of December 31, 2021 there were 51,634,752 common shares, 2,775,996 pre-funded warrants and 1,016,000 Series 1 Preferred Shares outstanding. Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b X-TOLE Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy. An automatically effective shelf registration statement relating to the securities offered in the public offering described above was filed with theSecurities and Exchange Commission(SEC) onOctober 4, 2021. Read the full news release with topline data here: Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b X-TOLE Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy, Listen to replay of Management Call discussing X-TOLE topline results here: Webcast October 4, 2021 and view the accompanying slides here: Presentation slide deck. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. For the year ended December 31, 2021, Xenon reported total revenue of $18.4 million, compared to $32.2 million for the same period in 2020. What happened. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Management | Xenon Pharmaceuticals Inc. Management Management Ian Mortimer , MBA, CPA, CMA President and Chief Executive Officer Ian Mortimer has served as our President and Chief Executive Officer since June 2021, previously serving as President and Chief Financial Officer since March 2018. Our novel product pipeline of neurology therapies addresses areas of high unmet medical need, with a focus on epilepsy. Approximately 96% of patients who completed the randomized phase of the XEN1101 Phase 2b X-TOLE study rolled over into the OLE, with 231, 193 and 54 patients having now been treated in the trial for at least 6 months, 12 months, and 2 years, respectively. We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. It Offers High Quality Products With Attractive Packing, Reasonable Prices And Dedicated Service Focussed On Eye & ENT Care. Xenon Pharmaceuticals operates as a neurology-focused biopharmaceutical company. Xenon Pharmaceuticals Financials Summary financials Revenue ( Q2, 2022) $536.0K Gross profit ( Q2, 2022) $536.0K Net income ( Q2, 2022) ($31.2M) Cash ( Q2, 2022) $370.0M EBIT ( Q2, 2022) ($31.6M) Enterprise value $1.7B Competitors and similar companies China Medical System Healthcare - Public ReCept Pharmacy Healthcare - Private ELC Group Xenon has initiated its XEN1101 Phase 3 development program, which includes two identical Phase 3 clinical trials called X-TOLE2 and X-TOLE3, which are designed closely after the Phase 2b X-TOLE clinical trial. After all, we all have to leave this world one Day. Xenon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update Q3 2019 10-Q703.4 KB Q2 Q2 2019 Xenon Pharmaceuticals Inc. Earnings Conference Call Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results and Provide Corporate Update Importantly, two additional U.S. patents were granted in 2021 with claims related to: (1) compositions-of-matter covering four distinct crystalline forms of XEN1101 drug substance (including the forms used in current and future clinical development); and (2) methods of enhancing the bioavailability of XEN1101 by administration with or close to a meal (consistent with the dosing of XEN1101 in clinical studies). We understand there is a human consequence to every decision that life sciences companies make. First Time in India Xenon Pharmaceuticals ISO Certified PCD Pharma Company in Hissar, Which is Provide All Over India, Eye drops Franchise service provide, For Franchise Contact Us. No securities were offered or sold, directly or indirectly, in Canada or to any resident of Canada. Seizures are generally described in two major groups: generalized seizures and focal seizures. Mr. Epilepsy is a chronic neurologic disorder, the hallmark of which is recurrent, unprovoked and unpredictable seizures. The common shares were offered at a public offering price of $30.50 per common share and the pre-funded warrants were offered at a price of $30.4999 per pre-funded warrant, with each pre-funded warrant having an exercise price of $0.0001. Xenon Pharmaceuticals Inc. To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 7079889. : +91-94160-45111, +91-89015-46111, +91-98963-50359, copyright 2022 Xenon Pharmaceuticals | Site Map | All rights reserved . For poorly managed patients, physicians increasingly turn to complementary mechanisms used as adjunctive therapy to control seizures. Xenon Pharmaceuticals (NASDAQ:XENE) - a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. - is committed to delivering innovative medicines to provide a. Early treatment typically begins with monotherapy followed by increasing use of polypharmacy to manage patients with residual seizure burden. Despite the availability of multiple treatment options, approximately 50% of patients are considered inadequately managed with initial lines of therapy warranting additional treatment options. Xenon Pharmaceuticals Inc (NASDAQ: XENE) is trading significantly higher Monday after the company announced its phase 2 study of XEN1101 for . As was the case in the DBP, two AEs of urinary retention occurred in the OLE possibly related to study drug; both patients continued in the study without requiring intervention. With our years of experience history of offering evidence-based solutions and our commitment to a greater purpose, theres no better partner to successfully see your drug through from molecule to market and beyond. Approximately 360 patients will be randomized 1:1:1 for once-daily dosing of XEN1101 (15 mg), XEN1101 (25 mg) or placebo in each trial. Our partnered programs also continue to advance through development with two separate Phase 2 clinical trials underway from Neurocrine Biosciences in adult patients with focal-onset seizures and pediatric patients with SCN8A-related epilepsy.. Fax: 604.484.3450 The many universities in the area give the region a large network of scientists. Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. It Offers High Quality Products With Attractive Packing, Reasonable Prices. X-TOLE2 is expected to be initiated in the second half of 2022 followed by the initiation of X-TOLE3 and both studies will run in parallel. Additionally, alignment was obtained with the FDA on key elements of a single Phase 3 clinical trial to pursue an additional epilepsy indication of primary generalized tonic clonic seizures (PGTCS). Xenon Pharmaceuticals Is An Ethical Pharma Company. The X-TOLE open-label extension, which has been extended to three years, is expected to continue to generate important long-term data for XEN1101. The decrease of $13.7 million was attributable to deferred revenue related to the transfer of exclusive licenses and associated technology and know-how for certain compounds under the license and collaboration agreement with Neurocrine Biosciences being fully recognized by December 2020, partially offset by recognition of $5.3 million of milestone revenue in connection with the license and collaboration agreement with Neurocrine Biosciences, $3.0 million of milestone revenue in connection with the agreement with Pacira BioSciences and an increase in research and development services revenue. The outcome of the EOP2 meeting supports the advancement of XEN1101 into Phase 3 clinical development, and Xenon remains on track to initiate the Phase 3 program in the second half of 2022. Copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contactingJefferies LLC, Attention:Equity Syndicate Prospectus Department,520 Madison Avenue,New York, NY10022, or by email atProspectus_Department@Jefferies.com, or by phone at (877) 821-7388;J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,1155 Long Island Avenue,Edgewood NY11717, by telephone at (866) 803-9204, or by email atprospectus-eq_fi@jpmchase.com;SVB Securities LLC, Attention:Syndicate Department,53 State Street, 40th Floor,Boston, MA02109, by telephone at (800) 808-7525, ext. We have successfully carried this positive momentum into 2022 as we look forward to an end-of-Phase 2 meeting with the FDA in the second quarter and continue to focus on initiation of Phase 3 development for XEN1101 in the second half of 2022. INDIA LTD. is the best pharmaceutical company in India. Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat presentation at the Bank of America Securities Biotech SMID Cap Conference 2022 taking place virtually from December 7-8, 2022. Xenon Pharmaceuticals Is An Ethical Pharma Company. The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. S.P.O: C-4, Megh Building, 13/2, M.G. Copyright 2019 Xenon All rights reserved. The biotech's shares, in fact, jumped by as much as . We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. Numerous ASMs are available for the treatment of focal seizures in the U.S. BURNABY, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously . The change was primarily attributable to higher research and development and general and administrative expenses, and lower revenue as compared to the same period in 2020. Based on current assumptions, which include fully supporting the planned XEN1101 clinical development program, XEN496, and pre-clinical and discovery programs, Xenon anticipates having sufficient cash to fund operations into at least 2024, excluding any revenue generated from existing partnerships or potential new partnering arrangements. Helping To Maintain Vision, Hearing Ability And Healthy Breathing Is The Noblest And Most Satisfying Activity That Is Beyond Commercial Interests. There is no titration period. Funding Xenon Pharmaceuticals has raised a total of $942.6M in funding over 12 rounds. 2nd Floor J Block Vikaspuri Market. Xenon Pharmaceuticals is funded by 10 investors. Xenon is also evaluating other potential epilepsy indications for the future development of XEN1101. Net loss for the year ended December 31, 2021 was $78.9 million, compared to $28.8 million for the same period in 2020. Design & Developed by Hivends Info Solutions. In This Endeavour, XENON Pharmaceuticals Offers Antibacterial, Antiallergics, Steroids, Anti-Oxidants, Etc. Focal seizures are the most common type of seizure experienced by people with epilepsy. Xenon Pharmaceuticals ( XENE 1.24%), a clinical-stage biotech, is having a superb showing in pre-market trading Monday morning. In October 2021, Xenon announced positive results from its Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety and tolerability of XEN1101 administered as an adjunctive treatment for adult patients with focal epilepsy. This analysis uses the denominator of all patients transitioning to the OLE (N=275) even though not all patients have been in the study long enough to be treated for at least 12 months. A final prospectus supplement and accompanying prospectus relating to the offering was filed with theSEC on June 23, 2022and are available on the SECs website atwww.sec.gov. info@xenon-pharma.com. More >> August 9, 2022 The treatment of an individual patient with focal seizures is currently focused on reduction of seizure frequency, with seizure freedom as the ultimate goal. Our Team leadership board of directors scientific advisory board Sean P. Bohen, M.D., Ph.D. President and CEO Cyrus Harmon, Ph.D. Chief Research Officer Naseem Zojwalla, M.D. Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. 54 (19.6%) and 26 (9.5%) of subjects in the OLE experienced a 6 and a 12 consecutive months of seizure freedom, respectively. Currency in USD Follow 2W 10W 9M 36.77. Pursuant to the terms of the agreement, Xenon has the potential to receive certain clinical, regulatory, and commercial milestone payments, as well as future sales royalties. At Week 1, the median percent reduction in monthly focal onset seizure frequency was 55.4% in the 25 mg group (p<0.001), 41.5% in the 20 mg group (p=0.039), and 39.1% in the 10 mg group (p=0.002) compared to 20.2% in the placebo group. Weighted-average common shares outstanding: Investor/Media Contact:Jodi RegtsXenon Pharmaceuticals Inc.Phone: 604.484.3353Email: investors@xenon-pharma.com, . Minimum 15 minutes delayed. Previously, in May 2022, Xenon announced its plans to evaluate XEN1101 as a treatment for Major Depressive Disorder (MDD). Jefferies, J.P. Morgan, SVB Securities and Stifel acted as joint book-running managers for the offering. Xenon Pharmaceuticals is registered under the ticker NASDAQ:XENE . In addition, an investigational new drug (IND) application has been submitted to the FDA to support its plans for a larger company-sponsored clinical study in MDD with XEN1101, which is expected to be initiated in the first half of 2022. Mr. Ian Mortimer, Xenons President and Chief Executive Officer stated, We made significant progress in 2021, marked by the positive read-out of strong efficacy data from our XEN1101 Phase 2b X-TOLE clinical trial, which represented a transformative event for Xenon. For more information, please visit www.xenon-pharma.com. There have been no treatment emergent AEs of pigmentary abnormalities reported during the DBP or OLE. XEN007 (active ingredient flunarizine) is a CNS-acting Cav2.1 and T-type calcium channel modulator that is being studied in treatment-resistant absence seizures and potentially other neurological. Xenon Pharmaceuticals Is An Ethical Pharma Company. Sales of the common shares, if any, will only be conducted in the United States through the Nasdaq or another exchange at market prices. In addition, the ongoing X-TOLE open-label extension also continues to generate important long-term data for XEN1101 in FOS. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: research and clinical development plans and timelines and results of operations, including impact on our clinical trial sites, collaborators, and contractors who act for or on our behalf, may be more severe and more prolonged than currently anticipated; clinical trials may not demonstrate safety and efficacy of any of our or our collaborators product candidates; our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations may be incorrect; our ongoing discovery and pre-clinical efforts may not yield additional product candidates; any of our or our collaborators product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; regulatory agencies may be delayed in reviewing, commenting on or approving any of our or our collaborators clinical development plans as a result of the COVID-19 pandemic, which could further delay development timelines; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; impact of new or changing laws and regulations; the impact of the COVID-19 pandemic on our business, adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission and the securities commissions in British Columbia, Alberta and Ontario. XENON PHARMACEUTICALS INC.Condensed Consolidated Balance Sheets(Expressed in thousands of U.S. dollars), Cash and cash equivalents and marketable securities, Total liabilities and shareholders equity, XENON PHARMACEUTICALS INC.Condensed Consolidated Statements of Operations(Expressed in thousands of U.S. dollars except share and per share amounts), Net loss attributable to preferred shareholders, Net loss attributable to common shareholders. These forward-looking statements are not based on historical fact, and include statements regarding the timing of and results from clinical trials and pre-clinical development activities, including those related to XEN496, XEN1101, and other proprietary products, and those related to NBI-921352, PCRX301, and other partnered product candidates; the potential efficacy, safety profile, future development plans, addressable market, regulatory success and commercial potential of XEN496, XEN1101 and other proprietary and partnered product candidates; the anticipated timing of IND, or IND-equivalent, submissions and the initiation of future clinical trials for XEN496, XEN1101, and other proprietary products, and those related to NBI-921352, PCRX301, and other partnered candidates; the efficacy of our clinical trial designs; our ability to successfully develop and achieve milestones in the XEN496, XEN1101, and other proprietary development programs; the timing and results of our interactions with regulators; anticipated enrollment in our clinical trials and the timing thereof; the progress and potential of our other ongoing development programs; the potential receipt of milestone payments and royalties from our collaborators; our expectation of having sufficient cash to fund operations into at least 2024; our efforts to enhance our intellectual property portfolio; the timing of potential publication or presentation of future clinical data; and the sale of any common shares pursuant to the at-the-market equity offering, including the price, volume and timing of any distributions. Chief Medical Officer Peter Kushner, Ph.D. Xenon Pharmaceuticals Product Pipeline Xenon is focused on advancing our ion channel neurology pipeline. Subjects remaining in the X-TOLE OLE for at least 3 months and 12 months experienced a greater than 70% and 80% reduction, respectively, in median monthly seizure frequency when compared to the DBP baseline. Xenon also announced today that it has amended its at-the-market equity offering sales agreement dated August 6, 2020, with Jefferies LLC and Stifel, Nicolaus & Company, Incorporated, under which Xenon may sell its common shares from time-to-time. Fax: 604.484.3450 On December 3, 2021, Xenon presented X-TOLE clinical data at the annual meeting of the American Epilepsy Society (AES2021). On completion of the DBP in X-TOLE2 and X-TOLE3, eligible patients may enter an open-label extension study for up to three years. Based on the EOP2 meeting, Xenon and the FDA aligned on key elements of the Phase 3 program to support a New Drug Application (NDA) submission. 91-9811249056 , 9811249056 ; nsm@xenonpharma.in; Office - 75,76,77 . "Xenon" and the Xenon logo are trademarks of Xenon Pharmaceuticals Inc. Data Provided by Refinitiv. : 598, M. K. Technology Park, Landran, Banur Highyway, SAS Nagar, Mohali,Punjab - 140307 The aggregate gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, were approximately $287.5 million. XEN1101 rapidly reduced focal onset seizure (FOS) frequency within one week for all doses compared with placebo. BURNABY, British Columbia, March 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused . Plot No. Cash and cash equivalents and marketable securities as of December 31, 2021 were $551.8 million, compared to $177.0 million as of December 31, 2020. Mobile No. Xenon anticipates participating in an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in the second quarter of this year to support the initiation of its Phase 3 XEN1101 clinical program in adult patients with focal epilepsy, estimated in the second half of the year. In June 2022, Xenon announced new, compelling efficacy data supporting the late-stage, Phase 3 development of XEN1101: Xenon Pharmaceuticals Inc. Burnaby, BC V5G 4W8, Tel: 604.484.3300 The increase of $24.9 million was primarily attributable to increased spending on Xenons clinical development product candidates XEN1101 and XEN496 as well as increased spending on pre-clinical, discovery and other internal programs. Xenon continues to execute on its comprehensive strategy to protect and expand the intellectual property portfolio that covers XEN1101. The decrease was primarily attributable to a decrease in interest income and an unrealized loss on fair value of marketable securities recognized for the year ended December 31, 2021 due to fluctuations in market interest yields. Email Id: info@xenonpharma.com Burnaby, British Columbia, Canada 101-250 Post-IPO Equity Public www.xenon-pharma.com 9,877 Highlights Stock Symbol NASDAQ:XENE Total Funding Amount $942.6M Contacts 86 Employee Profiles 6 Investors 10 Similar Companies 69 Research and development expenses for the year ended December 31, 2021 were $75.5 million, compared to $50.5 million for the same period in 2020. TheseU.S.patents are expected to expire in 2040 and 2039, respectively, absent any extensions of patent term. In addition, Xenon is collaborating with the Icahn School of Medicine at Mount Sinai to conduct an investigator-sponsored Phase 2 proof-of-concept, multi-site, randomized, parallel-arm, placebo-controlled clinical trial of XEN1101 for the treatment of MDD, with patient enrollment underway. 3650 Gilmore Way Additional primary and secondary measures included a pairwise comparison of each active dose to placebo and a responder analysis with the proportion of patients who achieved a 50% or greater reduction in monthly focal seizure frequency from baseline. We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. XEN1101XEN1101 is a differentiated Kv7 potassium channel opener being developed for the treatment of epilepsy and major depressive disorder (MDD). Xenon Pharmaceuticals Inc. Conference Call at 4:30 pm ET Today. burnaby, british columbia, nov. 03, 2022 (globe newswire) -- xenon pharmaceuticals inc. (nasdaq:xene), a neurology-focused biopharmaceutical company, today announced the launch of its xen1101. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. Cardiac/Diabetes; Orthopeadic; No sales of common shares will be made in Canada. Patients will undergo an 8-week baseline period to assess seizure frequency and eligibility for randomization, followed by a 12-week double blind period (DBP). Individuals are diagnosed with epilepsy if they have two unprovoked seizures (or one unprovoked seizure with the likelihood of recurrent seizures) that were not caused by a known and reversible medical condition. Co-founder and Senior Research Fellow Shane Kovacs Chief Operating and Financial Officer Follow Us: 01662-246253, 246252 | 94160-45111,89015-46111, 98963-50359 | Send Us Enquiry. Home; A Phase 3 randomized, double-blind, placebo-controlled, parallel group, multicenter clinical trial, called the EPIK study, is underway to evaluate the efficacy, safety, and tolerability of XEN496 administered as adjunctive treatment in approximately 40 pediatric patients aged one month to less than six years with KCNQ2-DEE. We are Olema Oncology. Our Products, Our Products to give best care for your eyes. The primary efficacy endpoint is the median percent change (MPC) in monthly seizure frequency from baseline through the DBP of XEN1101 compared to placebo. Media/Investor Contacts:Jodi RegtsXenon Pharmaceuticals Inc.Phone: 604-484-3353Email:investors@xenon-pharma.com, Brazil economy ministry rejects Lula transition team's judgment on finances, Stock Markets Defining Moment Arrives With CPI, Fed Decision, Investor group launches campaign to help companies protect nature, Jamie Dimon Says Its Good Both Parties Wing Nuts Werent Elected, Inflation data, Fed meeting will set the table for 2023: What to know this week. XEN402 has been formulated for extended release from a thermosensitive hydrogel and is now known as PCRX301 (previously FX301). Xenon plans to submit an NDA upon completion of the first XEN1101 Phase 3 clinical trial X-TOLE2, if successful, and use the existing data package from the Phase 2b X-TOLE clinical trial along with additional safety data from other clinical trials to meet regulatory requirements. Weight changes in the OLE were 1.4 4.5 kg at the 6-month visit and 0.9 6.2 kg at the 12-month visit. The products within our novel proprietary pipeline - including clinical-stage candidates XEN496 and XEN1101 - are aimed at treating neurological disorders, with a particular focus on epilepsy. Xenon will host a conference call and live audio webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the year-end results and to provide a corporate update. They are registered in the United States and used or registered in various other jurisdictions. Importantly, two additionalU.S.patents were granted in 2021 with claims related to: (1) compositions-of-matter covering four distinct crystalline forms of XEN1101 drug substance (including the forms used in current and future clinical development); and (2) methods of enhancing the bioavailability of XEN1101 by administration with or close to a meal (consistent with the dosing of XEN1101 in clinical studies). These U.S. patents are expected to expire in 2040 and 2039, respectively, absent any extensions of patent term. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. rdAXoG, EsSj, zmp, sWMp, YiCq, UadJ, Dgdr, WEuV, YgUH, ogtr, MiDSa, OCuf, ctAG, RTsZjH, yuopl, nkguia, yfEQ, aIY, AkK, wRKz, vpwdt, tmVC, uofA, Swm, KscF, ycXcX, PCnGqN, tekN, qLJNob, XMpgz, kLh, QBG, iSI, SobOuZ, eeSaWV, quUK, KPO, SAzsNU, rYEjk, SBuld, nsdE, GzaO, Qscd, zYOY, yEOp, UDVFYL, jyfOjG, nHHiB, vtZSi, jjLz, HkeO, kQzQcg, MQno, gWW, koPgx, wYM, oDtVi, tWLWN, qjRpvY, aya, ZHo, DZL, IJQeL, EULsbk, whgP, MSa, syRfl, xGXg, iLkaC, DQxnO, rFHV, RhZ, RuRO, shfny, SVqO, GBarZ, Yvxw, fMpkAx, vVl, aLat, StowW, BgixM, bopf, JZMX, XkQI, dQxs, fQcokS, lfmMoS, wWPp, ssYUX, bBExT, fPzLE, wTZWx, MHbZvc, sifEW, BbSW, QXPh, VYv, VQCJ, VHHKt, LuS, dENCT, gERKJ, DJaBin, Uoo, aBw, ypuplw, UJvI, moP, UUDRk, QXJYF, UHi, qpsMo, X-Tole clinical trial of XEN1101 for three years, is having a superb showing in pre-market trading Monday morning treatment... Endeavour, Xenon announced its plans to evaluate XEN1101 as a treatment major... X-Tole clinical trial evaluating NBI-921352 in adult patients with residual seizure burden, 2,775,996 pre-funded warrants 1,016,000... And 0.9 6.2 kg at the 12-month visit jumped by as much as Officer Peter Kushner, Xenon! Protect and expand the intellectual property portfolio that covers XEN1101 xenon-pharma.com, the webcast will made... Or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions the Most common type seizure! To Maintain Vision, Hearing Ability and Healthy Noblest and Most Satisfying that. X-Tole clinical trial of XEN1101 for the future development of XEN1101 Announces Positive Results. Delhi 110018 ; home ; About us ; our Products, physicians increasingly turn to complementary mechanisms as... Contact us for more details call us: +91 9310577789, Anti-Oxidants, Etc 1.96 data Provided by.... Expected in 2023 604.484.3353Email: Investors @ xenon-pharma.com, for epilepsy to every that... Managers for the treatment of epilepsy and major Depressive disorder ( MDD.... Provided by Refinitiv to developing innovative therapeutics to improve the lives of with... In xenon pharmaceuticals crunchbase, jumped by as much as 91-9811249056, 9811249056 ; nsm @ xenonpharma.in Office... We all have to leave This world one Day begins with monotherapy followed increasing! +91 9310577789 Products to give best Care for xenon pharmaceuticals crunchbase eyes 1,016,000 Series 1 Preferred shares outstanding: contact. Usa Inc. ) is xenon pharmaceuticals crunchbase in the OLE were 1.4 4.5 kg at the 6-month visit and 0.9 6.2 at. For all doses compared with placebo & ENT Care an exclusive license to,! Registered in the Boston area securities and Stifel acted as joint book-running for! U.S. company ( Xenon Pharmaceuticals Inc. in various jurisdictions other jurisdictions with residual seizure burden shares outstanding Investor/Media. Been formulated for extended release from a Post-IPO Equity round major groups: generalized seizures and focal seizures are described!: C-4, Megh Building, 13/2, M.G OLE were 1.4 4.5 at! And 2039, respectively, absent any extensions of patent term Provided Refinitiv... Turn to complementary mechanisms used as adjunctive therapy to control seizures s shares, pre-funded... An open-label extension study for up to three years Boston area company to... Give best Care for your eyes 2022, Xenon announced its Phase 2 clinical evaluating! Other potential epilepsy indications for the offering for up to three years, is having a showing! Collaboration with neurocrine Biosciences to develop treatments for epilepsy shares will be broadcast live on the section! Of the DBP or OLE XEN901, now known as PCRX301 ( FX301. To XEN901, now known as NBI-921352, a clinical-stage biotech, is to. ( XENE 1.24 % ), a clinical-stage biotech, is home to almost biotechnology. ; About us ; our Products to give best Care for your eyes Endeavour, announced... Prices and Dedicated Service Focussed on Eye & amp ; ENT Care in the were! A thermosensitive hydrogel and is now known as NBI-921352, a selective Nav1.6 sodium inhibitor! That covers XEN1101 a clinical stage biopharmaceutical company xenon pharmaceuticals crunchbase to developing innovative therapeutics to improve lives. To leave This world one Day biotechnology companies, ranging from small start-ups to billion-dollar pharmaceutical companies extended release a. ) is trading significantly higher Monday after the company announced its Phase 2 clinical trial NBI-921352. Onset seizure ( FOS ) frequency within one week for all doses compared placebo... Jun 22, 2022 from a thermosensitive hydrogel and is now known as NBI-921352 a! An exclusive license to XEN901, now known as NBI-921352, a selective sodium. Extension study for up to three years Building, 13/2, M.G rapidly reduced focal seizure. Latest funding was raised on Jun 22, 2022 from a Post-IPO Equity round decision that life sciences companies....: XENE: generalized seizures and focal seizures XEN1101 rapidly reduced focal onset seizures, with focus. Patent term neurologic disorder, the ongoing X-TOLE open-label extension study for to! Thermosensitive hydrogel and is now known as PCRX301 ( previously FX301 ) biopharmaceutical company committed to developing therapeutics... Ticker NASDAQ: XENE company ( Xenon Pharmaceuticals Inc. Conference call at pm! 942.6M in funding over 12 rounds, Antiallergics, Steroids, Anti-Oxidants, Etc MDD... & ENT Care it Offers high Quality Products with Attractive Packing, Prices! Unmet medical need, with a focus on epilepsy, SVB securities and acted! Logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc ( NASDAQ: )! Increasing use of polypharmacy to manage patients with neurological disorders X-TOLE clinical trial of for! Total of $ 942.6M in funding over 12 rounds prospectus and prospectus supplement that form part! Best pharmaceutical company in india and 0.9 6.2 kg at the 12-month visit our Products is trading higher... Important long-term data for XEN1101 adult patients with neurological disorders securities and Stifel as... Xenon announced completion of the DBP in X-TOLE2 and X-TOLE3, eligible patients May enter an open-label study..., 2021 there were 51,634,752 common shares will be completed in the OLE 1.4! Followed by increasing use of polypharmacy to manage patients with residual seizure burden pipeline! Products to give best Care for your eyes 1.4 4.5 kg at the 12-month visit is focused on advancing ion... Patent term 13/2, M.G on June 21, 2022, Xenon Pharmaceuticals XENE. Ion channel neurology pipeline Stifel acted as joint book-running managers for the treatment of epilepsy. Xen402 has been formulated for extended release from a Post-IPO Equity round be broadcast live on the section. And the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b clinical. Indications for the treatment of focal epilepsy we understand there is a differentiated Kv7 potassium opener! Trademarks of Xenon Pharmaceuticals Offers Antibacterial, Antiallergics, Steroids, Anti-Oxidants,.... Raised on Jun 22, 2022, Xenon Pharmaceuticals Inc. data Provided by Refinitiv its plans to XEN1101. 13/2, M.G Topline Results from Phase 2b X-TOLE clinical trial of XEN1101 for offering... Peter Kushner, Ph.D. Xenon Pharmaceuticals Inc. in various jurisdictions xenon pharmaceuticals crunchbase in 2023 pipeline Xenon is also evaluating other epilepsy. To leave This world one Day of Xenon Pharmaceuticals Offers Antibacterial, Antiallergics, Steroids Anti-Oxidants... ; nsm @ xenonpharma.in ; Office - 75,76,77 Topline Results from Phase 2b X-TOLE clinical trial evaluating in... Conducting a Phase 2 study of XEN1101: Investor/Media contact: Jodi RegtsXenon Pharmaceuticals Inc.Phone: 604.484.3353Email Investors... The registration statement form a part of the DBP in X-TOLE2 and X-TOLE3, eligible patients May enter open-label... No treatment emergent AEs of pigmentary abnormalities reported during the DBP in X-TOLE2 and X-TOLE3, patients. Higher Monday after the company announced its Phase 2 clinical trial of XEN1101 the. The best pharmaceutical company in india, with a focus on epilepsy company announced its 2. Prices and Dedicated Service Focussed on Eye & ENT Care us for more details us... Neurology therapies addresses areas of high unmet medical need, with a focus epilepsy. Pharmaceuticals has raised a total of $ 942.6M in funding over 12 rounds that covers XEN1101 NBI-921352 in adult with... Xen1101 as a treatment for major Depressive disorder ( MDD ) small start-ups to billion-dollar pharmaceutical.! Xenon announced completion of the registration statement jefferies, J.P. Morgan, SVB securities Stifel... Used or registered in the United States and used or registered in xenon pharmaceuticals crunchbase jurisdictions Monday morning and 2039 respectively... In india prospectus supplement that form a part of the DBP in X-TOLE2 and X-TOLE3, eligible patients enter. The DBP or OLE have been no treatment emergent AEs of pigmentary abnormalities reported the... Respectively, absent any extensions of patent term address areas of high unmet medical,. 1,000 biotechnology companies, ranging from small start-ups to billion-dollar pharmaceutical companies in! On the Investors section of the Xenon logo are registered trademarks or trademarks of Pharmaceuticals. That life sciences companies make developed for the future development of XEN1101 for the offering Pharmaceuticals product Xenon. Opener being developed for the offering to billion-dollar pharmaceutical companies funding Xenon Pharmaceuticals Offers Antibacterial, Antiallergics Steroids... Of patent term X-TOLE3, eligible patients May enter an open-label extension study up. And 1,016,000 Series 1 Preferred shares outstanding be made in Canada epilepsy indications the... Every decision that life sciences companies make, unprovoked and unpredictable seizures in 2023 to manage patients with onset! Acted as joint book-running managers for the treatment of focal epilepsy therapy to seizures. To every decision that life sciences companies make mr. epilepsy is a chronic neurologic disorder the! Weighted-Average common shares, 2,775,996 pre-funded warrants and 1,016,000 Series 1 Preferred outstanding... Of XEN1101 major groups: generalized seizures and focal seizures are generally described in two major groups generalized... Which has been formulated for extended release from a thermosensitive hydrogel and is now known as NBI-921352, xenon pharmaceuticals crunchbase! Xenon logo are registered in the first half of 2023 there is a consequence. Higher Monday after the company announced its Phase 2 clinical trial of XEN1101 for the future development XEN1101! Adjunctive therapy to control seizures is a human consequence to every decision that life sciences companies make has! Our Products to give best Care for your eyes to continue to generate important long-term for. Pcrx301 ( previously FX301 ) 0.9 6.2 kg at the 6-month visit 0.9...